Browse WFIKKN2

Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF07679 Immunoglobulin I-set domain
PF00014 Kunitz/Bovine pancreatic trypsin inhibitor domain
PF01759 UNC-6/NTR/C345C module
PF00095 WAP-type (Whey Acidic Protein) 'four-disulfide core'
Function

Protease-inhibitor that contains multiple distinct protease inhibitor domains. Probably has serine protease- and metalloprotease-inhibitor activity. Inhibits the biological activity of mature myostatin, but not activin (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0032091 negative regulation of protein binding
GO:0042692 muscle cell differentiation
GO:0043392 negative regulation of DNA binding
GO:0043393 regulation of protein binding
GO:0045861 negative regulation of proteolysis
GO:0048747 muscle fiber development
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051101 regulation of DNA binding
GO:0051146 striated muscle cell differentiation
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0060021 palate development
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004867 serine-type endopeptidase inhibitor activity
GO:0008191 metalloendopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between WFIKKN2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of WFIKKN2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of WFIKKN2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.1090.0109
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.4280.0595
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.7120.241
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0550.894
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0550.93
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0280.897
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of WFIKKN2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WFIKKN2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WFIKKN2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WFIKKN2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WFIKKN2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of WFIKKN2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between WFIKKN2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolWFIKKN2
NameWAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2
Aliases WFIKKNRP; WFDC20B; WAP four-disulfide core domain 20B; hGASP-1; WAP, FS, Ig, two KU and NTR module related p ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting WFIKKN2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.